Opportunistic Fragility Fracture Risk Estimates From Radiographs
- Disease/Condition
- Osteoporosis
- Drug/Device/Intervention
- IbexBH Software
- Study type
- Observational
- Intervention type
- device
- Primary sponsor
- University of Exeter
- Location
- Exeter, United Kingdom
- Phase
- N/A
- Start date
- Jul 01, 2023
- End date
- Sep 01, 2024
- Enrollment
- 552 participants
T-scores as calculated by IbexBH and DXA
The proposed study will predict a patients' risk of having osteoporosis by using a
 combination of the IBEX BH (Bone Health) software outputs and other clinical risk factors
 such as age, gender, medical history and lifestyle. A comparison will be made between the
 IBEX BH prediction and the one calculated in current clinical practice using a tool called
 FRAX (Fracture Risk Assessment Tool) which combines clinical risk factors with results from a
 Dual Energy X-ray Absorptiometry (DXA) assessment.
 
 The study involves conducting these assessments on several new anatomies including Knee,
 Ankle and Pelvis, to extend the market reach and clinical utility of IBEX BH. The expected
 outcome of the study is that the IBEX BH will offer better decision support to clinicians in
 terms of referral on for a DXA scan or osteoporosis investigations than available today.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06110442
- Type
- Device Trial
Access comprehensive clinical trial information for NCT06110442 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Exeter and is currently Recruiting. The study focuses on Osteoporosis. Target enrollment is 552 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.